Walter Low, Phd Email & Phone Number

London, Gb

Courgenay, Ch

Andover, Hampshire, Gb

Strategic and Operational Drug Development ConsultingCurrent projects include:- Strategic Lead for a biosimilar drug development program at a global pharmaceutical company, leading an international team and alliance partner to complete development activities and ensure a timely launch- Supporting a biotech startup with fundraising initiatives and planning efforts, including devising comprehensive antibody drug development strategies to accelerate product pipeline growth and attract investor engagement.

Reykjavik, -, Is

Alvotech (NASDAQ: ALVO) is a fully integrated specialty multinational biopharmaceutical company focused on the development and manufacturing of high-quality biosimilar medicines for global markets. Alvotech operates across centres of excellence in Iceland, Germany, Switzerland and the United States. CAHT is the China joint venture company of Alvotech and Changchun High & New Technology Industries• Member of the Alvotech leadership team, providing overall strategic leadership & oversight for a portfolio of biosimilar development programs to global program teams. Program Head for AVT02 (biosimilar to Humira), AVT04 (biosimilar to Stelara) both achieving regulatory approval and launched globally and AVT03 (biosimilar to Prolia / Xgeva) and AVT23 (biosimilar to Xolair)• Lead multiple project teams of cross-functional experts spanning CMC, Pre-Clinical and Clinical Development, Regulatory Affairs, Quality, Finance, Intellectual Property across Europe, US, India, Australia and China. Accountable for programs milestones and deliverables.• Joint Development Working Groups and partaker to the Steering Committees for key development alliance partners, e.g. Fuji Pharma (JP), TEVA (US), STADA (EU), JAMP (CA)

Gdańsk, Pomorskie, Pl

Polpharma Biologics is focused on the development and manufacturing of biosimilar and novel biologic drugs. Polpharma Biologics Group operates across centres of excellence in Poland, the Netherlands and Switzerland.Current position and responsibilities built up on previous role as Global Program Manager at bioeq GmbH which led to the successful advancement of Polpharma Biologics’ lead product, a biosimilar of natalizumab, from early CMC development to advanced clinical stages paving the way for a global commercialisation agreement with Sandoz (Novartis).• Member of Polpharma Biologics leadership team reporting to CEO and President of Management Board.• Lead, coordinate and control of global cross‐functional development teams and projects from early stage CMC development through to completion of Ph 1 and Ph 3 clinical studies and health authorities interactions.• Operations Committee and Steering Committee member providing review, guidance and oversight for overall operations of the global commercialisation agreement between Polpharma Biologics and Sandoz.

bioeq GmbH is a joint venture between the Polpharma Biologics and the Strüngmann Family Office (Santo Holding) and active in the development of biosimilar drugs for global markets• Member of bioeq management board, reporting to CEO and steering committee • Overarching coordination, control and completion of global cross‐functional development projects in house, at contract service providers (CROs & CMOs) and in collaboration with other pharma and biotech companies • Lead cross-functional strategic and operational plans for a portfolio of biosimilar programs from early development stage into clinical trials

PX’Therapeutics is a global orientated biopharmaceutical contract development and manufacturing organisation (CDMO), specialising in the development of therapeutic antibodies and proteins from early stage research up to clinical grade GMP manufacturing• Member of the senior management and executive board directly reporting to the CEO• Scientific Management responsibility for a multidisciplinary team of 14 at different locations

• Development and manufacturing of therapeutic antibodies and proteins from early stage R&D up to cGMP production for Ph I clinical trials• Responsibility for the planning and progression of customer projects and the management of daily operations within the Quality Control laboratories supporting the commercial and clinical product release

Microtest Diagnostics was spun out of Imperial College London with a mission to provide automated multiplex in-vitro diagnostic tests in the areas of Allergy, Autoimmune, Influenza and Infectious Disease with a desktop device at the point of care• Reporting to CEO, design and development of protein and antibody microarrays for the identification and quantification of antibodies and biomarkers in human sera• Development of multiplex immunoassay-based bio chips, associated lateral flow device and optical reader for clinical diagnostic applications (i.e. autoimmune, allergy, infectious diseases)

An early stage biotechnology spin-off company from Imperial College London focused on the discovery and development of Protein Transduction Technology

Research Associate, Department Of Biological Sciences

Post Doctoral, Immunology And Gene Therapy

Bsc, Msc, Phd, Biochemistry